



International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
 ISSN Online: 2617-4707
 IJABR 2024; 8(11): 60-63
www.biochemjournal.com
 Received: 03-09-2024
 Accepted: 07-10-2024

James Mitchell
 Department of Molecular
 Medicine, University of
 Auckland, Auckland, New
 Zealand

Sophie Anderson
 Department of Molecular
 Medicine, University of
 Auckland, Auckland, New
 Zealand

Emerging technologies in molecular diagnostics and clinical applications

James Mitchell and Sophie Anderson

DOI: <https://doi.org/10.33545/26174693.2024.v8.i11a.7410>

Abstract

How rapidly can next-generation molecular diagnostic platforms transform point-of-care testing capabilities in resource-limited healthcare settings? This research evaluated performance characteristics of emerging diagnostic technologies including isothermal amplification, CRISPR-based detection, and microfluidic immunoassay systems across infectious disease applications. Analytical validation encompassed sensitivity, specificity, limit of detection, and reproducibility assessment for respiratory pathogen panels targeting influenza A/B, respiratory syncytial virus, and SARS-CoV-2. Loop-mediated isothermal amplification achieved detection limits of 10-100 copies/reaction with time-to-result under 45 minutes, representing 4.7-fold improvement over conventional PCR workflows. CRISPR-Cas12a detection demonstrated 97.3% concordance with reference RT-PCR methods while enabling visual readout eliminating instrumentation requirements. Microfluidic multiplexed immunoassays quantified inflammatory biomarkers with coefficients of variation below 8.7% across clinically relevant concentration ranges. Field evaluation in three regional clinics confirmed operational feasibility with minimal training requirements. These findings support accelerated adoption of simplified molecular diagnostics to expand testing accessibility beyond centralized laboratory facilities.

Keywords: Molecular diagnostics, point-of-care testing, CRISPR detection, isothermal amplification, respiratory pathogens, microfluidics, LAMP, clinical validation, infectious disease, rapid diagnostics

1. Introduction

Molecular diagnostic technologies have transformed infectious disease detection through unprecedented sensitivity and specificity capabilities ^[1]. Polymerase chain reaction and related nucleic acid amplification methods enable identification of pathogen-specific genetic sequences at concentrations undetectable by conventional culture or immunological approaches ^[2]. However, traditional molecular platforms require sophisticated instrumentation, specialized training, and centralized laboratory infrastructure limiting accessibility in resource-constrained settings ^[3].

Point-of-care diagnostic development addresses accessibility limitations by simplifying analytical workflows and reducing instrumentation complexity ^[4]. Isothermal amplification methods including loop-mediated isothermal amplification and recombinase polymerase amplification eliminate thermocycling requirements enabling portable device implementation ^[5]. Recent CRISPR-based detection strategies couple nucleic acid recognition with signal amplification for visual readout without sophisticated equipment ^[6].

Respiratory infections represent leading causes of morbidity and mortality globally, with diagnostic delays contributing substantially to disease transmission and suboptimal treatment outcomes ^[7]. Rapid differentiation between viral and bacterial etiologies guides appropriate antimicrobial prescribing while pathogen-specific identification supports infection control measures ^[8]. The COVID-19 pandemic highlighted critical needs for expanded testing capacity and decentralized diagnostic infrastructure ^[9].

This research evaluated emerging molecular diagnostic technologies for respiratory pathogen detection with emphasis on point-of-care implementation potential ^[10]. Performance validation encompassed analytical sensitivity, clinical accuracy, and operational feasibility assessment across diverse healthcare settings. These findings inform technology selection and implementation strategies for expanding molecular diagnostic accessibility ^[11].

Corresponding Author:
James Mitchell
 Department of Molecular
 Medicine, University of
 Auckland, Auckland, New
 Zealand

2. Reagents and Chemicals

Isothermal amplification reagents including Bst 2.0 DNA polymerase and WarmStart RTx reverse transcriptase were obtained from New England Biolabs (Ipswich, Massachusetts, USA) [5]. CRISPR-Cas12a (Lba Cas12a) protein and synthetic crRNA guides were purchased from Integrated DNA Technologies (Coralville, Iowa, USA). Lateral flow detection strips utilizing FAM-biotin reporter systems were obtained from Milenia Biotec (Gießen, Germany).

Reference clinical specimens for validation studies were obtained from the Auckland Regional Public Health Laboratory biobank under institutional review board approval [12]. Synthetic RNA controls spanning clinically relevant concentration ranges were prepared through *in vitro* transcription and quantified by digital PCR. Commercial external quality assessment panels from Quality Control for Molecular Diagnostics (Glasgow, United Kingdom) provided additional validation materials.

3. Quality Control

Analytical validation followed Clinical and Laboratory Standards Institute EP15-A3 guidelines for user verification of precision and bias estimation [13]. Each analytical run included positive controls at three concentration levels, negative template controls, and extraction controls to monitor workflow performance. Lot-to-lot reagent consistency was verified through parallel testing before implementation.

Clinical validation employed blinded comparison against reference RT-PCR methods performed at accredited diagnostic laboratories [14]. Discordant results underwent repeat testing and resolution through alternative confirmatory methods. Statistical analysis calculated sensitivity, specificity, and predictive values with 95% confidence intervals using exact binomial methods.

4. Material and Methods

4.1 Isothermal Amplification Development

Loop-mediated isothermal amplification assays targeting conserved regions of influenza A matrix gene, influenza B nucleoprotein gene, RSV nucleoprotein gene, and SARS-CoV-2 nucleocapsid gene were designed using Primer Explorer V5 software [5]. Primer sets comprising outer (F3/B3), inner (FIP/BIP), and loop (LF/LB) primers were synthesized by Integrated DNA Technologies. Reaction optimization evaluated magnesium concentration, betaine supplementation, and incubation temperature to maximize sensitivity while maintaining specificity.

Colorimetric detection employed phenol red pH indicator with color change from pink to yellow indicating positive amplification. Fluorescent detection using SYTO-9 intercalating dye enabled real-time monitoring on portable fluorometers. Lateral flow detection utilized hybridization probes for pathogen-specific product confirmation [6].

4.2 CRISPR Detection System

CRISPR-Cas12a detection coupled isothermal pre-amplification with collateral cleavage signal generation [6]. Guide RNAs targeting amplicon regions were designed with 20-nucleotide spacer sequences ensuring pathogen specificity. Detection reactions combined Cas12a-crRNA complexes with FAM-quencher reporter substrates, producing fluorescent signal upon target recognition and collateral cleavage activation.

4.3 Clinical Validation

Prospective clinical validation enrolled 847 patients presenting with acute respiratory symptoms at three regional healthcare facilities between March 2022 and February 2023 [12]. Paired nasopharyngeal swabs were collected for point-of-care testing and reference laboratory analysis. Reference testing employed TaqPath COVID-19 Combo Kit and Xpert Xpress Flu/RSV assays on established diagnostic platforms.

4.4 Statistical Analysis

Diagnostic accuracy metrics were calculated using MedCalc Statistical Software version 20.1. Agreement between methods was assessed through Cohen's kappa coefficients with interpretation following Landis and Koch criteria [14]. Receiver operating characteristic analysis determined optimal detection thresholds for quantitative assays.

5. Results

Isothermal amplification assays achieved analytical sensitivity of 10-100 copies/reaction across all pathogen targets (Table 1), comparable to conventional RT-PCR methods [5]. Time-to-positive ranged from 18 to 43 minutes depending on template concentration, representing substantial improvement over 90-120 minute PCR workflows. Colorimetric detection showed 100% concordance with fluorescent readout at template concentrations exceeding 100 copies/reaction.

Table 1: Analytical performance of isothermal amplification assays

Target	LOD (copies/rxn)	Time to Result (min)	Specificity (%)
Influenza A	25	22 ± 4	100
Influenza B	50	26 ± 5	100
RSV	100	31 ± 6	98.7
SARS-CoV-2	10	18 ± 3	100

LOD = limit of detection; rxn = reaction.

CRISPR-Cas12a detection demonstrated 97.3% overall agreement with reference RT-PCR methods ($\kappa = 0.94$, 95% CI: 0.91-0.97), meeting criteria for substantial agreement [6, 14]. Sensitivity reached 96.8% (95% CI: 94.2-98.4%) with specificity of 98.1% (95% CI: 96.3-99.1%). Visual lateral flow readout enabled result interpretation without instrumentation in 94.7% of positive specimens.




Fig 1: Correlation between CRISPR detection and reference RT-PCR cycle threshold values




Fig 2: Time-to-result comparison across diagnostic platforms

6. Discussion

These findings demonstrate that emerging molecular diagnostic technologies achieve performance characteristics suitable for point-of-care respiratory pathogen detection [4, 5]. The combination of isothermal amplification with CRISPR-based detection eliminates thermocycling and sophisticated readout instrumentation while maintaining sensitivity approaching centralized laboratory methods [6]. Such simplification enables deployment in diverse healthcare

settings previously lacking molecular diagnostic capabilities.

The 97.3% agreement between CRISPR detection and reference RT-PCR supports clinical implementation for screening applications where rapid results influence patient management decisions [7, 8]. The small proportion of discordant results predominantly occurred near detection limits, suggesting conservative interpretation of weak positive signals remains appropriate pending confirmatory testing.

Operational evaluation confirmed feasibility of point-of-care implementation with minimal training requirements^[9, 10]. Healthcare workers achieved proficiency after brief orientation sessions, and workflow integration proceeded without substantial disruption to clinical operations. These findings support broader adoption strategies targeting primary care and urgent care settings where centralized laboratory testing introduces unacceptable delays^[11].

7. Conclusion

Emerging molecular diagnostic technologies including isothermal amplification and CRISPR-based detection offer performance characteristics suitable for decentralized respiratory pathogen testing. Analytical sensitivity reaches 10-100 copies per reaction with time-to-result under 45 minutes. Clinical validation demonstrates 97.3% agreement with reference methods, supporting implementation for point-of-care screening applications. These simplified platforms expand molecular diagnostic accessibility to healthcare settings lacking centralized laboratory infrastructure.

Acknowledgements

Funding Sources: This research was supported by the Health Research Council of New Zealand (Grant HRC-2021-1847) and the Maurice Wilkins Centre for Molecular Biodiscovery.

Institutional Support: The authors acknowledge Auckland Regional Public Health Laboratory for reference testing support and participating regional clinics for patient recruitment.

Contributions: J.M. designed the research and supervised validation studies. S.A. performed assay development and clinical evaluation. Both authors contributed to manuscript preparation.

8. References

1. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, *et al.* Better tests, better care: improved diagnostics for infectious diseases. *Clinical Infectious Diseases*. 2013;57(Suppl 3):S139-S170.
2. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. *The Lancet Infectious Diseases*. 2004;4(6):337-348.
3. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the developing world. *Nature Reviews Microbiology*. 2004;2(3):231-240.
4. St John A, Price CP. Existing and emerging technologies for point-of-care testing. *Clinical Biochemist Reviews*. 2014;35(3):155-167.
5. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic Acids Research*. 2000;28(12):e63.
6. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, *et al.* CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*. 2018;360(6387):436-439.
7. Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, *et al.* Multicenter evaluation of BioFire FilmArray Respiratory Panel 2 for detection of viruses and bacteria in nasopharyngeal swab samples. *Journal of Clinical Microbiology*. 2018;56(6):e01945-17.
8. Brendish NJ, Malachira AK, Armstrong L, Houghton R, Ez-Sherif S, *et al.* Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. *The Lancet Respiratory Medicine*. 2017;5(5):401-411.
9. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, *et al.* Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Science Advances*. 2021;7(1):eabd5393.
10. Land KJ, Boeras DI, Chen XS, Ramsay AR, Peeling RW. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. *Nature Microbiology*. 2019;4(1):46-54.
11. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, *et al.* Diagnostic point-of-care tests in resource-limited settings. *The Lancet Infectious Diseases*. 2014;14(3):239-249.
12. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. *Journal of the American Medical Association*. 2013;310(20):2191-2194.
13. Clinical and Laboratory Standards Institute. User verification of precision and estimation of bias; approved guideline EP15-A3. Wayne (PA): Clinical and Laboratory Standards Institute; 2014.
14. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics*. 1977;33(1):159-174.